The FB23-2 compound not only showed specific inhibition against FTO and proliferation against the AML cancer cell line in vitro, but also inhibited the progression of leukemia and prolonged the survival time in an in vivo AML model [16]. The gene discussed is FTO; the disease is acute myeloid leukemia.